• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4670601)   Today's Articles (15)
For: Walz DT, DiMartino MJ, Griswold DE. The pharmacological profile of auranofin, an orally active gold compound. Scand J Rheumatol Suppl 1983;51:16-25. [PMID: 6426049 DOI: 10.3109/03009748309095339] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Number Cited by Other Article(s)
1
Onodera T, Momose I, Kawada M. Potential Anticancer Activity of Auranofin. Chem Pharm Bull (Tokyo) 2019;67:186-191. [DOI: 10.1248/cpb.c18-00767] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
2
Doak B, Over B, Giordanetto F, Kihlberg J. Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. ACTA ACUST UNITED AC 2014;21:1115-42. [DOI: 10.1016/j.chembiol.2014.08.013] [Citation(s) in RCA: 282] [Impact Index Per Article: 25.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
3
Madeira J, Renschler C, Mueller B, Hashioka S, Gibson D, Klegeris A. Novel protective properties of auranofin: Inhibition of human astrocyte cytotoxic secretions and direct neuroprotection. Life Sci 2013;92:1072-80. [DOI: 10.1016/j.lfs.2013.04.005] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Revised: 03/17/2013] [Accepted: 04/15/2013] [Indexed: 12/22/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA